10-Q: Schrodinger Inc. Reports Q1 2024 Results: Revenue Declines Amidst Shifting Drug Discovery Focus

Schrodinger Inc. experienced a significant decrease in revenue during the first quarter of 2024, primarily due to a decline in drug discovery revenue, while software revenue saw a modest increase.

Summary

• Schrodinger Inc. reported a net loss of $54.7 million for the first quarter of 2024, compared to a net income of $129.1 million in the same period last year.
• Total revenue decreased by 44% year-over-year, from $64.8 million to $36.6 million.
• Software products and services revenue increased slightly by 4% to $33.4 million, while drug discovery revenue plummeted by 90% to $3.2 million.
• The company's operating expenses increased by 13% to $86.3 million, driven primarily by a 24% increase in research and development expenses.
• The company's cash, cash equivalents, restricted cash, and marketable securities totaled $435.7 million as of March 31, 2024.
• Schrodinger sold 282,963 shares of common stock under its at-the-market offering program for net proceeds of $7.6 million during the quarter.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While software revenue is up slightly and the company has a strong cash position, the significant drop in drug discovery revenue and the overall net loss are concerning. The increased operating expenses and reliance on future capital raises also contribute to a negative sentiment.

Positives

• Software products and services revenue saw a modest increase of 4% year-over-year.
• Hosted software revenue increased by 61% due to increased spend from existing customers and new customer acquisitions.
• The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next 24 months.

Negatives

• Total revenue decreased by 44% year-over-year, primarily due to a significant decline in drug discovery revenue.
• Drug discovery revenue decreased by 90% year-over-year, primarily due to the timing and amount of collaboration milestones achieved.
• The company reported a net loss of $54.7 million for the quarter, compared to a net income of $129.1 million in the same period last year.
• Operating expenses increased by 13% year-over-year, driven by a 24% increase in research and development expenses.

Risks

• The company's future success depends on its ability to increase software sales, increase revenue from drug discovery collaborations, and successfully develop and commercialize drug products.
• The company's quarterly and annual results may fluctuate significantly, which could adversely impact the value of its common stock.
• The company may require additional capital to fund its operations, and if it is unable to raise additional capital on acceptable terms, its business could be harmed.
• The company relies on third parties to conduct clinical trials and manufacture product candidates, and these third parties may not perform satisfactorily.
• The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials.
• The company's internal information technology systems may fail or suffer security breaches, which could result in a material disruption of services and compromise sensitive information.
• The company's future success depends on its ability to retain key executives and attract, retain, and motivate qualified personnel.
• The company is pursuing multiple business strategies and may encounter difficulties in managing its multiple business units and its growth.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 24 months. The company plans to utilize its existing cash primarily to fund its software and drug discovery activities.

Management Comments

• The company plans to evaluate and assess the data package from the SOS1 program to determine next steps and plans for further investment in the program.
• The company anticipates reporting initial data from the Phase 1 clinical trial of SGR-1505 in late 2024 or 2025.
• The company anticipates reporting initial data from the Phase 1 clinical trial of SGR-2921 in late 2024 or 2025.
• The company expects to initiate a Phase 1 clinical trial of SGR-3515 in patients with solid tumors in the third quarter of 2024.

Industry Context

The decrease in drug discovery revenue reflects a shift in the company's focus towards its proprietary drug discovery programs, which may result in fewer collaborative programs and milestone payments over time. The company is also facing increasing competition from companies utilizing artificial intelligence and other computational approaches for drug discovery.

Comparison to Industry Standards

• The company's software revenue growth of 4% is modest compared to some other software companies in the life sciences sector, which have seen higher growth rates.
• The 90% decline in drug discovery revenue is significant and highlights the volatility and uncertainty associated with drug discovery collaborations, which is common in the industry.
• The increase in research and development expenses is consistent with the trend of biopharmaceutical companies investing heavily in their pipelines, but the company's overall operating expenses are also increasing.
• The company's cash position of $435.7 million is relatively strong compared to many other companies in the biotechnology sector, providing a buffer for future operations and development activities.
• The company's reliance on third-party contract research organizations and contract manufacturing organizations is a common practice in the industry, but it also introduces risks related to supply chain and quality control.

Corporate Governance

Related Party Transactions

• The company paid consulting fees of $105,000 to a member of its board of directors for the three months ended March 31, 2024.
• The Bill and Melinda Gates Foundation issued a grant under which it agreed to pay the company directly for certain licenses and services provided to a specified group of third-party organizations.
• The company recognized $490,000 in drug discovery contribution revenue related to funds received under an agreement with the Bill and Melinda Gates Foundation.
• The company recognized revenue of $810,000 under a collaboration agreement with Structure Therapeutics.

Stakeholder Impact

• Shareholders may be concerned about the significant decrease in revenue and the net loss reported for the quarter.
• Employees may be affected by the company's shift in focus and potential changes in resource allocation.
• Customers may be impacted by the company's ability to maintain and improve its software solutions and provide adequate support.
• Collaborators may be affected by the company's shift in focus towards its proprietary drug discovery programs.
• Creditors may be concerned about the company's financial performance and its ability to meet its obligations.

Next Steps

• The company plans to evaluate and assess the data package from the SOS1 program to determine next steps and plans for further investment in the program.
• The company anticipates reporting initial data from the Phase 1 clinical trial of SGR-1505 in late 2024 or 2025.
• The company anticipates reporting initial data from the Phase 1 clinical trial of SGR-2921 in late 2024 or 2025.
• The company expects to initiate a Phase 1 clinical trial of SGR-3515 in patients with solid tumors in the third quarter of 2024.

Key Dates

Keywords

Schrodinger, Drug Discovery, Software, Computational Platform, Pharmaceutical, Biotechnology, Clinical Trials, Revenue, Financial Results, Research and Development